136 related articles for article (PubMed ID: 30953675)
21. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients.
Chung YW; Bae HS; Song JY; Lee JK; Lee NW; Kim T; Lee KW
Int J Gynecol Cancer; 2013 May; 23(4):673-9. PubMed ID: 23542579
[TBL] [Abstract][Full Text] [Related]
22. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
24. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
25. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
26. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
27. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
28. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis.
Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859
[TBL] [Abstract][Full Text] [Related]
29. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
30. HE4 in the differential diagnosis of ovarian masses.
Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
[TBL] [Abstract][Full Text] [Related]
31. The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
Zhang M; Wang Y; Matyunina LV; Akbar A; McDonald JF
Cancer Lett; 2020 Jun; 480():15-23. PubMed ID: 32234315
[TBL] [Abstract][Full Text] [Related]
32. HE4 can help discriminate women with malignant ovarian
tumors only if CA125 levels are elevated.
Pitta Dda R; Sarian LO; Campos EA; Andrade LL; Sallum LF; Bragança JF; Campos Cde M; Derchain S
Int J Biol Markers; 2013; 28(4):e377-86. PubMed ID: 23828407
[TBL] [Abstract][Full Text] [Related]
33. Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients.
Ji T; Zheng ZG; Wang FM; Xu LJ; Li LF; Cheng QH; Guo JF; Ding XF
Asian Pac J Cancer Prev; 2014; 15(4):1739-43. PubMed ID: 24641401
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
Koutsaki M; Spandidos DA; Zaravinos A
Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
[TBL] [Abstract][Full Text] [Related]
35. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
37. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
39. Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer.
Zhu XL; Ren LF; Wang HP; Bai ZT; Zhang L; Meng WB; Zhu KX; Ding FH; Miao L; Yan J; Wang YP; Liu YQ; Zhou WC; Li X
World J Gastroenterol; 2019 Apr; 25(13):1580-1591. PubMed ID: 30983818
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
